These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8305412)

  • 1. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma.
    Hansen JB; Huseby NE; Sandset PM; Svensson B; Lyngmo V; Nordøy A
    Arterioscler Thromb; 1994 Feb; 14(2):223-9. PubMed ID: 8305412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro.
    Hansen JB; Huseby KR; Huseby NE; Ezban M; Nordøy A
    Thromb Res; 1997 Mar; 85(5):413-25. PubMed ID: 9076898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a).
    Lesnik P; Vonica A; Guérin M; Moreau M; Chapman MJ
    Arterioscler Thromb; 1993 Jul; 13(7):1066-75. PubMed ID: 8318508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients.
    Morishita E; Asakura H; Saito M; Yamazaki M; Ontachi Y; Mizutani T; Kato M; Matsuda T; Nakao S
    Atherosclerosis; 2001 Jan; 154(1):203-12. PubMed ID: 11137101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys.
    Abumiya T; Nakamura S; Takenaka A; Takenaka O; Yoshikuni Y; Miyamoto S; Kimura T; Enjyoji K; Kato H
    Arterioscler Thromb; 1994 Mar; 14(3):483-8. PubMed ID: 8123656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia.
    Kokawa T; Abumiya T; Kimura T; Harada-Shiba M; Koh H; Tsushima M; Yamamoto A; Kato H
    Arterioscler Thromb Vasc Biol; 1995 Apr; 15(4):504-10. PubMed ID: 7749862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.
    Cheung MC; Austin MA; Moulin P; Wolf AC; Cryer D; Knopp RH
    Atherosclerosis; 1993 Aug; 102(1):107-19. PubMed ID: 8257447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease.
    Berrettini M; Parise P; Ricotta S; Iorio A; Peirone C; Nenci GG
    Thromb Haemost; 1996 Mar; 75(3):395-400. PubMed ID: 8701396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.
    Harris GM; Stendt CL; Vollenhoven BJ; Gan TE; Tipping PG
    Am J Hematol; 1999 Mar; 60(3):175-80. PubMed ID: 10072106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypercholesterolemia in postmenopausal women. Metabolic defects and response to low-dose lovastatin.
    Arca M; Vega GL; Grundy SM
    JAMA; 1994 Feb; 271(6):453-9. PubMed ID: 8295321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages : relationship to tissue factor induction by cholesterol and oxidized LDL.
    Petit L; Lesnik P; Dachet C; Moreau M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1999 Feb; 19(2):309-15. PubMed ID: 9974412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II.
    Kawaguchi A; Miyao Y; Noguchi T; Nonogi H; Yamagishi M; Miyatake K; Kamikubo Y; Kumeda K; Tsushima M; Yamamoto A; Kato H
    Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):251-8. PubMed ID: 10634826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of lovastatin treatment on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia.
    Tilly-Kiesi M
    Metabolism; 1991 Jun; 40(6):623-8. PubMed ID: 1865826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cholesterol lowering on intravascular pools of TFPI and its anticoagulant potential in type II hyperlipoproteinemia.
    Hansen JB; Huseby KR; Huseby NE; Sandset PM; Hanssen TA; Nordøy A
    Arterioscler Thromb Vasc Biol; 1995 Jul; 15(7):879-85. PubMed ID: 7600119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
    Zitoun D; Bara L; Basdevant A; Samama MM
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):77-81. PubMed ID: 8548430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments.
    Lane DM; Alaupovic P; Knight-Gibson C; Dudley VS; Laughlin LO
    Am J Cardiol; 1995 Jun; 75(16):1124-9. PubMed ID: 7762498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease.
    Bilgen D; Sönmez H; Ekmekçi H; Ulutin T; Oztürk Z; Kökoğlu E; Bayram C; Soner A; Domaniç N
    Clin Biochem; 2005 Jan; 38(1):92-6. PubMed ID: 15607324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of lovastatin on concentrations and composition of lipoprotein subfractions.
    Nozaki S; Vega GL; Haddox RJ; Dolan ET; Grundy SM
    Atherosclerosis; 1990 Oct; 84(2-3):101-10. PubMed ID: 2282090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increases in dietary cholesterol and fat raise levels of apoprotein E-containing lipoproteins in the plasma of man.
    Cole TG; Patsch W; Kuisk I; Gonen B; Schonfeld G
    J Clin Endocrinol Metab; 1983 Jun; 56(6):1108-15. PubMed ID: 6841553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.